Ketotifen Unit Dose Stulln

Ketotifen, the active ingredient in Ketotifen Unit Dose Stulln, is an antihistamine (H1 receptor antagonist, mast cell stabilizer) presented as a unit dose ophthalmic preparation for ocular use. It treats allergic conjunctivitis, eye itching and seasonal allergic eye disease in patients who need topical relief.

GNH USA supplies Ketotifen Unit Dose Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketotifen is an ocular antihistamine that addresses allergic inflammation of the eye.

Allergic conjunctivitis: reduces redness, swelling and itching caused by allergen exposure. Eye itching: provides rapid relief of pruritus associated with seasonal allergies. Seasonal allergic eye disease: stabilises mast cells to prevent recurrent allergic episodes.

Ketotifen may cause local ocular reactions and, rarely, systemic effects.

Common Side Effects: - Burning or stinging sensation upon instillation. - Temporary blurred vision. - Mild eye irritation or foreign‑body sensation. - Redness of the conjunctiva. - Tearing or increased lacrimation.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema of the eyelids). - Persistent ocular pain or photophobia. - Corneal ulceration or keratitis. - Vision loss not attributable to other causes. - Systemic hypersensitivity (e.g., rash, urticaria).

Before using Ketotifen Unit Dose Stulln, consider the following safety measures.

Avoid use in patients with known hypersensitivity to ketotifen or any excipients. Do not apply if the ocular surface is infected or severely inflamed. Monitor for signs of worsening eye irritation or allergic reaction. Inform healthcare provider of concurrent ocular medications. Store at ambient temperature: keep in the original container, protect from moisture and light.

Ketotifen can interact with other ocular or systemic agents; review patient medication lists.

Major Interactions (Avoid): - Concurrent use of other mast‑cell stabilisers may increase local irritation. - Co‑administration with topical non‑steroidal anti‑inflammatory eye drops can heighten risk of corneal toxicity.

Moderate Interactions (Monitor Closely): - Systemic antihistamines may potentiate sedation if absorbed in small amounts. - Beta‑blocker eye drops could theoretically affect intra‑ocular pressure control. - Use with contact lenses may cause discomfort; advise removal before instillation.